Patents by Inventor Martin P. Maguire

Martin P. Maguire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10307557
    Abstract: A tracheal tube assembly includes an outer cannula configured to be positioned in a patient airway and an inner cannula configured to be disposed inside the outer cannula. The tracheal tube assembly further includes a flange member secured about the outer cannula, and an outer cannula connector coupled to a proximal end of the outer cannula. The outer cannula connector includes a compressible portion may be compressed while inserting or removing the inner cannula.
    Type: Grant
    Filed: January 19, 2016
    Date of Patent: June 4, 2019
    Assignee: COVIDIEN LP
    Inventors: Martin J. Bruggemann, James M. Ryan, Declan Kiernan, Alan Finneran, Seamus P. Maguire
  • Publication number: 20190142781
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: January 14, 2019
    Publication date: May 16, 2019
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20190022048
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventor: Martin P. MAGUIRE
  • Patent number: 10117848
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: November 6, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventor: Martin P. Maguire
  • Publication number: 20180280339
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: June 4, 2018
    Publication date: October 4, 2018
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Patent number: 10010523
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 3, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Patent number: 10010522
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: July 18, 2017
    Date of Patent: July 3, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Patent number: 10010524
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: July 20, 2017
    Date of Patent: July 3, 2018
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Publication number: 20180110752
    Abstract: The present invention includes surprisingly water-soluble salts of a phenylalkylamine compound that are potent antagonists of L-type calcium channels. Aqueous solutions including salts of the instant invention are formulated for nasal administration and provide a novel therapeutic platform for the treatment of stable angina, migraine, and cardiac arrhythmia, such as paroxysmal supraventricular tachycardia.
    Type: Application
    Filed: April 13, 2016
    Publication date: April 26, 2018
    Inventor: Martin P. MAGUIRE
  • Publication number: 20170312241
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20170312242
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: July 18, 2017
    Publication date: November 2, 2017
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Publication number: 20170312243
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: July 20, 2017
    Publication date: November 2, 2017
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Patent number: 9737503
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: August 22, 2017
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Publication number: 20160374982
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: September 12, 2016
    Publication date: December 29, 2016
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Patent number: 9463179
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: November 23, 2015
    Date of Patent: October 11, 2016
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Publication number: 20160074354
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: November 23, 2015
    Publication date: March 17, 2016
    Inventors: Martin P. MAGUIRE, Elise RIOUX, Harry J. LEIGHTON
  • Patent number: 9227918
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: June 16, 2014
    Date of Patent: January 5, 2016
    Assignee: Milestone Pharmaceuticals
    Inventors: Martin P. Maguire, Elise Rioux, Harry J. Leighton
  • Publication number: 20140296335
    Abstract: The present invention relates to the use of a pharmaceutically effective amount of an short-acting calcium channel blocking compound to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension before, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: June 16, 2014
    Publication date: October 2, 2014
    Inventors: Martin P. MAGUIRE, Elise Rioux, Harry J. Leighton
  • Patent number: 8501727
    Abstract: The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Grant
    Filed: August 20, 2009
    Date of Patent: August 6, 2013
    Assignee: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Dominik Herbart, Harry J. Leighton
  • Publication number: 20110144087
    Abstract: The present invention relates to short-acting calcium channel blocking compounds and their use to treat ischemic heart conditions, cardiac arrhythmias, hypertensive crisis in an emergency room setting, hypertension in general, hypertension been.) fore, during, or after surgery, no-reflow phenomenon following reperfusion, and diseases associated with decreased skeletal muscle blood flow. The invention also relates to pharmaceutical compositions formulated for use in such methods and to kits for such methods.
    Type: Application
    Filed: August 20, 2009
    Publication date: June 16, 2011
    Applicant: Milestone Pharmaceuticals Inc.
    Inventors: Martin P. Maguire, Dominik Herbart, Harry J. Leighton